EntreMed regains compliance with NASDAQ $1.00 minimum closing bid price requirement

EntreMed, Inc. (Nasdaq: ENMDD), today announced receipt of a letter from the NASDAQ Stock Market stating that the Company has regained compliance with the $1.00 minimum closing bid price requirement and that, accordingly, it has determined to continue the listing of EntreMed's common stock on the NASDAQ Capital Market.

Previously, EntreMed had been notified by the NASDAQ Stock Market that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days.  In order to regain compliance with the rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days.  This requirement was met on July 15, 2010, the tenth consecutive trading day when the closing bid price of the Company's common stock was over $1.00.

"Maintaining a listing on the NASDAQ Capital Market is an important part of our corporate strategy," commented Michael M. Tarnow, Executive Chairman of EntreMed.  "The Board and Senior Management Team have taken great strides to regain NASDAQ compliance and we are grateful for the continued support of our investors while overcoming this obstacle."

Source:

EntreMed, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.